The CSIR–Centre for Cellular and Molecular Biology (CCMB) in Hyderabad has long been described, in the understated language of officialdom, as a “premier research organisation in frontier areas of modern biology.” Its alumni and discoveries—from DNA fingerprinting to population genomics—have quietly shaped India’s scientific landscape. With its August 2026 PhD call, expanded internships, and targeted hiring for the Phenome India CSIR Health Cohort, CCMB is now visibly reorganising itself around the era of big biology.
The new doctoral intake focuses on epigenetics, structural biology, and infection biology—three domains that sit at the heart of contemporary life sciences. Epigenetics students will probe how chemical marks and chromatin architecture regulate gene expression without altering DNA sequence, work that has implications for everything from development and ageing to diabetes and cancer. Structural biology projects aim to resolve the three-dimensional shapes of proteins and complexes at near-atomic resolution, using crystallography and cryo-EM to understand how molecules interact and how drugs might modulate them.
Infection biology, the third pillar, reflects lessons from recent and ongoing outbreaks. CCMB researchers plan to dissect how viruses, bacteria, and other pathogens enter cells, evade immune detection, and persist in reservoirs. In a country where infectious diseases remain a major burden even as non-communicable conditions rise, such mechanistic insights feed directly into vaccine design, diagnostics, and therapeutics.[
Parallel to the PhD call, the institute has launched a Summer Training Programme, opening its labs and computational facilities to a wider pool of students. For many, this will be their first exposure to high-throughput sequencing machines, advanced microscopes, and the bioinformatics pipelines that increasingly define modern biology. CCMB has long seen training as core to its mandate, and its profile as a Centre of Excellence and incubator for life science startups underscores that dual role.
The recruitment of bioinformatics and molecular biology specialists for the Phenome India CSIR Health Cohort marks another pivot. Phenome India aims to link genomic variation with rich phenotypic and clinical data across large, diverse Indian populations. Executed well, it could generate a resource that powers studies of complex diseases, drug response, and population health for decades.
Building such a cohort at scale demands more than sequencing machines. It requires robust pipelines for sample handling, data curation, quality control, and analysis—areas where CCMB has been steadily building capacity. The expansion in specialist hiring indicates an understanding that bioinformatics is not an add-on but a central nervous system for the project.
The stakes are high. Countries that manage to assemble well-annotated, representative genomic cohorts will be better placed to develop population-specific risk scores, tailor therapies, and negotiate from a position of strength with global pharma on trials and pricing. For India, with its enormous genetic diversity and disease burden, the upside is particularly large—but so are the risks of misuse or inequity if governance lags.
CCMB’s history offers both reassurance and caution. It has contributed to landmark advances such as the development of Indian DNA fingerprinting, the discovery of heart-disease-linked mutations prevalent in the subcontinent, and characterisation of population structure. It has also been a hub for public engagement and education, opening its doors through outreach programmes.
As it scales up training and genomic research capacity, the institute will need to extend that engagement into the digital realm: explaining to citizens why their data is valuable, how it will be protected, and what recourse they have if things go wrong. Bioethics cannot remain a narrow speciality when whole populations are being enrolled, literally and figuratively, into big biology.
For young scientists eyeing a career in life sciences, CCMB’s moves send a clear signal. The most consequential biology of the coming years will not be confined to single genes or pathways; it will play out in the interaction between genomes, phenomes, and environments, mediated by algorithms and large cohorts. Training at a place that sits at that intersection is likely to be as much about coding and statistics as pipettes and Petri dishes.
If the institute manages to marry its tradition of rigorous bench science with the demands of data-intensive genomics, CCMB could once again serve as a template—this time for how India can leapfrog into the front ranks of genomic medicine while still speaking in its own scientific and ethical accents.
-Ajanya Prakasn
